Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,110 shares of the biopharmaceutical company's stock after selling 1,476 shares during the quarter. ProShare Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $1,438,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Capital World Investors lifted its stake in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after acquiring an additional 92,101 shares during the period. Vanguard Group Inc. lifted its stake in Alnylam Pharmaceuticals by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after acquiring an additional 98,303 shares during the period. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after buying an additional 1,245,195 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $1.91 during trading on Tuesday, reaching $291.87. 164,620 shares of the company's stock were exchanged, compared to its average volume of 915,794. Alnylam Pharmaceuticals, Inc. has a 1 year low of $146.79 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market capitalization of $38.06 billion, a P/E ratio of -134.34 and a beta of 0.17. The company's fifty day simple moving average is $259.09 and its 200-day simple moving average is $254.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same period in the previous year, the company earned ($0.16) earnings per share. The company's revenue was up 20.2% compared to the same quarter last year. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on ALNY shares. Chardan Capital increased their price target on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Needham & Company LLC reissued a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, March 21st. HC Wainwright reissued a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Finally, Scotiabank increased their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $319.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.